Chief, Thoracic Oncology, Memorial Sloan Kettering Cancer Center
Oncology
Dr. Charles M. Rudin, MD
|
|
Give Review
Charles Rudin is an expert in the field of Oncology. He studied medicine at University of Chicago Pritzker School of Medicine. University of Chicago Pritzker School of Medicine is ranked 10 in research and 19 in primary care medicine He over the years received 1 awards: "Elected Member". Dr. Charles M. Rudin is a published doctor. He published 32 publications, including: 'Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes.' He accepts all Medicare patients.
Publications
- Small Cell Lung Cancer: Can recent advances in biology and molecular biology be translated into improved outcomes?
- Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes.
- Medians and Milestones in Describing the Path to Cancer Cures: Telling "Tails".
- DNA methylation in small cell lung Cancer defines distinct disease subtypes and correlates with high expression of EZH2.
- Repurposing the antihelmintic mebendazole as a hedgehog inhibitor.
- Molecularly targeted therapies in non-small-cell lung Cancer annual update 2014.
- Evaluation of azacitidine and entinostat as sensitization agents to cytotoxic chemotherapy in preclinical models of non-small cell lung Cancer.
- Clinical Characteristics and Course of 63 Patients with BRAF Mutant Lung Cancers.
- Phase I trial of seneca valley virus (NTX-010) in children with relapsed/refractory solid tumors: A report of the children's oncology group.
- RET Mutations in Neuroendocrine Tumors: Including Small-Cell Lung Cancer.
- Effective treatment of diverse Medulloblastoma models with mebendazole and its impact on tumor angiogenesis.
- A Prospective Study of Tumor Suppressor Gene Methylation as a Prognostic Biomarker in Surgically Resected Stage I to IIIA Non-Small-Cell Lung Cancers.
- Combining the pan-aurora kinase inhibitor AMG 900 with histone deacetylase inhibitors enhances antitumor activity in prostate Cancer.
- A Randomized, Phase 2 Trial of Docetaxel with or without PX-866, an Irreversible Oral Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Relapsed or Metastatic ...
- Using multiplexed assays of oncogenic drivers in lung Cancers to select targeted drugs.
- Systemic therapy, clinical outcomes, and overall survival in locally advanced or metastatic pulmonary carcinoid: a brief report.
- SOX2 expression is an early event in a murine model of EGFR mutant lung Cancer and promotes proliferation of a subset of EGFR mutant lung adenocarcinoma cell lines.
- MYC, MAX, and Small Cell Lung Cancer.
- Survival after community diagnosis of early stage non-small cell lung Cancer.
- The Twist Box Domain Is Required for Twist1-induced Prostate Cancer Metastasis.
- Alterations of immune response of non-small cell lung Cancer with Azacytidine.
- Age and sex differences in the incidence of esophageal adenoCarcinoma: results from the Surveillance, Epidemiology, and End Results (SEER) Registry (1973-2008).
- Epigenetic therapy in non-small-cell lung Cancer: targeting DNA methyltransferases and histone deacetylases.
- The future of epigenetic therapy in solid tumours-lessons from the past.
- Hedgehog pathway inhibition radiosensitizes non-small cell lung Cancers.
- Phase 2 study of pemetrexed and itraconazole as second-line therapy for metastatic nonsquamous non-small-cell lung Cancer.
- Inhibition of TWIST1 Leads to Activation of Oncogene-Induced Senescence in Oncogene-Driven Non-Small Cell Lung Cancer.
- Poly(?-amino ester) Nanoparticle Delivery of TP53 Has Activity against Small Cell Lung Cancer In Vitro and In Vivo.
- Combination treatment with ABT-737 and chloroquine in preclinical models of small cell lung Cancer.
- Molecular Characterization of Acquired Resistance to the BRAF Inhibitor Dabrafenib in a Patient with BRAF-Mutant Non-Small-Cell Lung Cancer.
- RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung Cancer.
Schools
U Of Chgo Div Of Bio Sci Pritzker Sch Of Med
University of Chicago
Procedures Preformed
- Cardiac MRI (Magnetic Resonance Imaging) of Heart or Chest
- Thoracentesis
Conditions Treated
- Adrenal Gland Cancer
- Anemia
- Bladder Cancer
- Brain and Nervous System Cancer (incl. Gliomas, Astrocytoma, Schwannoma, Medulloblastoma, Chordoma)
- View All
Doctors Specialties
- Medical Oncology
- Oncology
Accepted Insurances
Awards
- Elected Member
Education
-
University of Chicago -
University of Chicago Pritzker School of Medicine
Drug Facts
| NPI NUMBER | 1467483404 | |
| NPPES Provider LastName | RUDIN | |
| NPPES Provider FirstName | CHARLES | |
| NPPES Provider ZIPCode | 10065 | |
| NPPES Provider State | NY | |
| Specialty Description | Hematology | |
| Total Claim Count | 35.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1467483404 |
| Last Name Of The Provider | RUDIN |
| First Name Of The Provider | CHARLES |
| View All |
Similar Doctors
|
|
Dr. Ronald Blum, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Shumei Kato, MD |
|
|
Dr. Sandra M. Lombardo, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Justin M. Watts, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Sunandana Chandra, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Malini D. Sur, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Wiley Wilson, DO
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Robin G. Manson, MD |
|
|
Dr. Aki Morikawa, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jiahuai Tan, MD |